

**PRESS RELEASE**  
**Babraham Research Campus**

**15 May 2009**  
**Cambridge, UK**

**Babraham Bioscience Technologies appoints Derek Jones as CEO**

Babraham Bioscience Technologies (BBT) has appointed Derek Jones, as its new CEO. Formerly Chief Business Officer of BBT, Derek has brought a wealth of experience to the Babraham Research Campus - over 20 years in the pharmaceutical industry as both a scientist and in business development, with first hand experience of establishing biomedical ventures.

Initially a medicinal chemist with Merck, Derek moved into business and corporate development at Chiroscience, successfully negotiating several multi million pound licensing agreements. In 2000, he co-founded his first company, BioWisdom, an IT/Drug discovery company.

Derek was appointed COO at DanioLabs in 2002, a therapeutics company using zebrafish as a model organism for drug discovery, where he grew the company from 4 to 34 employees and raised around £10 million for VC backed companies, before selling DanioLabs to Vastox, now Summit Plc, for £15 million in 2007.

Commenting on his appointment he said, "BBT plays such an important role in the local bio-community as a home for 30 fledgling bioscience companies, and access to the world-class science from the Babraham Institute. I can see many opportunities here, and I look forward to building upon our success to date."

Dr David Brown, Chairman of the Board of BBT said, "Derek brings exactly the experience and approach required at BBT. Derek is a creative business professional and also a fine manager and colleague. The Board of BBT is delighted with his appointment."

**Contact details:**

Dr Claire Cockcroft,  
Head, External Relations  
Babraham Institute  
Email: [claire.cockcroft@bbsrc.ac.uk](mailto:claire.cockcroft@bbsrc.ac.uk)

Tel: +44 (0)1223 496260  
Fax: +44 (0)1223 496002

Derek Jones,  
Chief Executive Officer  
Babraham Bioscience Technologies Ltd  
Email: [derek.jones@babraham.co.uk](mailto:derek.jones@babraham.co.uk)

Tel: +44 (0)1223 496262  
Fax: +44 (0)1223 496020

Babraham Bioscience Technologies Ltd  
Babraham Research Campus  
Cambridge CB22 3AT  
United Kingdom

**Notes for Editors**

**Babraham Bioscience Technologies Ltd** is the wholly-owned subsidiary and trading arm of the Babraham Institute. Coalescing scientific, technological and commercial excellence, BBT delivers the Knowledge Transfer remit of the Institute through the wider landscape of the Babraham Research Campus, catalysing opportunities for enterprise across the academic and commercial divide. BBT brings together all the elements to support innovation and enable the successful exploitation of research in the biomedical sector based on technologies emanating from the Babraham Institute and bioventures relocating to the Babraham Research Campus. Website: [www.babraham.com](http://www.babraham.com)

**The Babraham Research Campus** is the UK's leading knowledge-driven Biomedical Park where world-class research, business know-how and entrepreneurial excellence come together to stimulate effective knowledge transfer and bridge the academic and commercial divide. The campus provides a unique and highly successful environment that actively fosters innovation and plays a pivotal role for biomedical start-up companies in the Cambridge region and with delivering innovation at the frontiers of biomedical research. BBT has taken a prominent role regionally, initiating and leading partnerships to promote knowledge and skills flow and has established a reputation for successfully translating innovative science into viable business opportunities through partnerships for wealth creation. This is stimulating inward investment to the campus and contributing to regional development.

**The Babraham Institute**, an independent charitable organisation located six miles south-east of Cambridge, is an institute of the Biotechnology and Biological Sciences Research Council. Carrying out world-leading innovative research and advanced training with relevance to the biomedical, biotechnological, pharmaceutical and healthcare communities, the institute underpins government's national responsibilities for healthcare research and training. Research focuses on the mechanisms of cell signalling and gene regulation, which underlie normal cellular processes and functions, and on how their failure or abnormality may lead to disease. The latest technologies are being used to study the basis of conditions such as neurodegenerative disorders, foetal abnormality, cancer and diseases of the immune and cardiovascular systems. The commercialisation of the Institute's research is managed by its trading subsidiary, Babraham Bioscience Technologies Ltd. Website: [www.babraham.ac.uk](http://www.babraham.ac.uk)